Terms: = Brain cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809
1187 results:
1. The
Ampudia-Mesias E; Cameron CS; Yoo E; Kelly M; Anderson SM; Manning R; Abrahante Lloréns JE; Moertel CL; Yim H; Odde DJ; Saydam N; Saydam O
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674001
[TBL] [Abstract] [Full Text] [Related]
2. Expression of STAT3 and hypoxia markers in long-term surviving malignant glioma patients.
Dvorakova K; Skarkova V; Vitovcova B; Soukup J; Vosmikova H; Pleskacova Z; Skarka A; Bartos MC; Krupa P; Kasparova P; Petera J; Rudolf E
BMC Cancer; 2024 Apr; 24(1):509. PubMed ID: 38654280
[TBL] [Abstract] [Full Text] [Related]
3. Lactoferrin mediates epithelial-mesenchymal transformation by regulating the PI3K/AKT/mtor pathway to inhibit nasopharyngeal carcinoma metastasis.
Xu M; Fan Y; Zou G; Yang Q; Xu F
Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):130-135. PubMed ID: 38650146
[TBL] [Abstract] [Full Text] [Related]
4. Multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy.
Du Y; Li R; Fu D; Zhang B; Cui A; Shao Y; Lai Z; Chen R; Chen B; Wang Z; Zhang W; Chu L
CNS Neurosci Ther; 2024 Apr; 30(4):e14717. PubMed ID: 38641945
[TBL] [Abstract] [Full Text] [Related]
5. Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors.
Cheng Y; Dai Y; Tang H; Lu X; Xie J; Xie W; Zhang Q; Liu Y; Lin S; Yao H; Shang H; Yang K; Liu H; Wu X; Zhang J; Zhang X; Xue L; Wu ZB
Acta Neuropathol Commun; 2024 Apr; 12(1):61. PubMed ID: 38637883
[TBL] [Abstract] [Full Text] [Related]
6. Exploring the combined anti-cancer effects of sodium butyrate and celastrol in glioblastoma cell lines: a novel therapeutic approach.
Kartal B; Denizler-Ebiri FN; Güven M; Taşpınar F; Canpınar H; Çetin S; Karaduman T; Küççüktürk S; Castresana J; Taşpınar M
Med Oncol; 2024 Mar; 41(5):97. PubMed ID: 38532150
[TBL] [Abstract] [Full Text] [Related]
7. Cerebellar phenotypes in germline PTEN mutation carriers.
Gambini D; Ferrero S; Bulfamante G; Pisani L; Corbo M; Kuhn E
Neuropathol Appl Neurobiol; 2024 Apr; 50(2):e12970. PubMed ID: 38504418
[TBL] [Abstract] [Full Text] [Related]
8. Just a spoonful of metformin helps the medicine go down.
Tzaridis T; Wechsler-Reya RJ
J Clin Invest; 2024 Mar; 134(6):. PubMed ID: 38488006
[TBL] [Abstract] [Full Text] [Related]
9. Hypoxia-induced TREM1 promotes mesenchymal-like states of glioma stem cells via alternatively activating tumor-associated macrophages.
Dong M; Zhang X; Peng P; Chen Z; Zhang Y; Wan L; Xiang W; Liu G; Guo Y; Xiao Q; Wang B; Guo D; Zhu M; Yu X; Wan F
Cancer Lett; 2024 May; 590():216801. PubMed ID: 38479552
[TBL] [Abstract] [Full Text] [Related]
10. Discrete Mechanistic Target of Rapamycin Signaling Pathways, Stem Cells, and Therapeutic Targets.
Jhanwar-Uniyal M; Zeller SL; Spirollari E; Das M; Hanft SJ; Gandhi CD
Cells; 2024 Feb; 13(5):. PubMed ID: 38474373
[TBL] [Abstract] [Full Text] [Related]
11. Daurisoline suppress glioma progression by inhibiting autophagy through PI3K/AKT/mtor pathway and increases TMZ sensitivity.
Yin HT; Hui-Lu ; Yang JH; Li Q; Li M; Zhao QQ; Wen ZP
Biochem Pharmacol; 2024 May; 223():116113. PubMed ID: 38460907
[TBL] [Abstract] [Full Text] [Related]
12. Effectively α-Terpineol Suppresses Glioblastoma Aggressive Behavior and Downregulates KDELC2 Expression.
Jin JS; Chou JM; Tsai WC; Chen YC; Chen Y; Ong JR; Tsai YL
Phytomedicine; 2024 May; 127():155471. PubMed ID: 38452695
[TBL] [Abstract] [Full Text] [Related]
13. Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities.
Ezzati S; Salib S; Balasubramaniam M; Aboud O
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396993
[TBL] [Abstract] [Full Text] [Related]
14. Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment.
Hatae R; Kyewalabye K; Yamamichi A; Chen T; Phyu S; Chuntova P; Nejo T; Levine LS; Spitzer MH; Okada H
JCI Insight; 2024 Apr; 9(7):. PubMed ID: 38386420
[TBL] [Abstract] [Full Text] [Related]
15. Antiproliferative effect of Potentilla fulgens on glioblastoma cancer cells through downregulation of Akt/mtor signaling pathway.
Kandemir SI; Ipek P
J Cancer Res Ther; 2023 Oct; 19(7):1818-1824. PubMed ID: 38376284
[TBL] [Abstract] [Full Text] [Related]
16. Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.
Nghiemphu PL; Vitte J; Dombi E; Nguyen T; Wagle N; Ishiyama A; Sepahdari AR; Cachia D; Widemann BC; Brackmann DE; Doherty JK; Kalamarides M; Giovannini M
J Neurooncol; 2024 Apr; 167(2):339-348. PubMed ID: 38372904
[TBL] [Abstract] [Full Text] [Related]
17. Repeat surgery of recurrent glioma for molecularly informed treatment in the age of precision oncology: A risk-benefit analysis.
Alhalabi OT; Dao Trong P; Kaes M; Jakobs M; Kessler T; Oehler H; König L; Eichkorn T; Sahm F; Debus J; von Deimling A; Wick W; Wick A; Krieg SM; Unterberg AW; Jungk C
J Neurooncol; 2024 Apr; 167(2):245-255. PubMed ID: 38334907
[TBL] [Abstract] [Full Text] [Related]
18. Tenacissoside H repressed the progression of glioblastoma by inhibiting the PI3K/Akt/mtor signaling pathway.
Dong J; Qian Y; Zhang W; Xu J; Wang L; Fan Z; Jia M; Wei L; Yang H; Luo X; Wang Y; Jiang Y; Huang Z; Wang Y
Eur J Pharmacol; 2024 Apr; 968():176401. PubMed ID: 38331340
[TBL] [Abstract] [Full Text] [Related]
19. PI3K/mtor is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.
Duchatel RJ; Jackson ER; Parackal SG; Kiltschewskij D; Findlay IJ; Mannan A; Staudt DE; Thomas BC; Germon ZP; Laternser S; Kearney PS; Jamaluddin MFB; Douglas AM; Beitaki T; McEwen HP; Persson ML; Hocke EA; Jain V; Aksu M; Manning EE; Murray HC; Verrills NM; Sun CX; Daniel P; Vilain RE; Skerrett-Byrne DA; Nixon B; Hua S; de Bock CE; Colino-Sanguino Y; Valdes-Mora F; Tsoli M; Ziegler DS; Cairns MJ; Raabe EH; Vitanza NA; Hulleman E; Phoenix TN; Koschmann C; Alvaro F; Dayas CV; Tinkle CL; Wheeler H; Whittle JR; Eisenstat DD; Firestein R; Mueller S; Valvi S; Hansford JR; Ashley DM; Gregory SG; Kilburn LB; Nazarian J; Cain JE; Dun MD
J Clin Invest; 2024 Feb; 134(6):. PubMed ID: 38319732
[TBL] [Abstract] [Full Text] [Related]
20. MAEL in human cancers and implications in prognostication and predicting benefit from immunotherapy over VEGFR/mtor inhibitors in clear cell renal cell carcinoma: a bioinformatic analysis.
Tao J; Cui J; Xu Y; Fan Y; Hong G; Zhou Q; Wang G; Li L; Han Y; Xu C; Wang W; Cai S; Zhang X
Aging (Albany NY); 2024 Jan; 16(3):2090-2122. PubMed ID: 38301040
[No Abstract] [Full Text] [Related]
[Next]
